Crysvita® is a recombinant fully human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23 (FGF23).
By blocking excess FGF23 in patients, Crysvita® is intended to increase phosphate reabsorption in the kidney and increase the production of vitamin D, which enhances intestinal absorption of phosphate and calcium in patients with X linked hypophosphatemia.

Marketed by Kyowa Kirin International in

  • Germany
  • Netherlands
  • Luxembourg
  • UK
  • Sweden
  • UAE
  • Israel
  • Canada
  • Italy